Semaglutide for Smoking Cessation in Patients With Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07059377
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 100 participants
- Registry
-
NCT07059377
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT07059377. Randomized; no masking; primary purpose treatment. Start 2026-02-13 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide for Smoking Cessation in Patients With Diabetes
- Acronym
- GLP1-SC
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Nicotine Addiction
- Condition
- Tobacco Dependence
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Nicotine replacement
- Lead sponsor
- Ottawa Heart Institute Research Corporation
Record details
- Record id
cardio:ct-nct07059377- Content hash
6f6f76064bd2125adeec410cf26d1aa305224f4c174d934ebe948f3d66e82ebf